FDA's Social Media Insight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA's Social Media Insight
Guidance offered on how to deal with off-label information requests.


Pharmaceutical Technology
Volume 36, Issue 2, pp. 12


Stephanie Sutton
Dedicated social media recommendations from FDA may not yet have materialized, but the agency is beginning to address some of the industry's questions in this area. At the end of 2011, FDA released a draft guidance titled Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices, which includes recommendations on responding through online channels such as forums and chat rooms.

According to the guidance, many firms encounter requests for off-label information about their products through websites, discussion boards, and other electronic forums, and FDA recognizes that firms are capable of responding to such requests in a "truthful, non-misleading, and accurate manner." Indeed, FDA acknowledges that it can be in the best interest of public health for companies to reply to these requests because other participants in the discussion may not be able to provide accurate information.

The guidance discusses responses to both non-public information requests, such as a one-on-one email or telephone call, and public requests, such as a request on an online forum. The latter type is more complicated because firms must ensure that their response does not communicate unapproved information to those who have not asked for it.

If a firm responds to unsolicited requests for off-label information in the manner described in the draft guidance, FDA said it will not use such responses as evidence of a firm's intent that the product be used for unapproved or cleared uses.

Stephanie Sutton is an associate editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here